You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Bulk Pharmaceutical API Sources for GLYCINE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for GLYCINE

Vendor Vendor Homepage Vendor Sku API Url
ChemExper Chemical Directory ⤷  Start Trial sJX`BDdvu@@ ⤷  Start Trial
Specs ⤷  Start Trial AB-131/40217813 ⤷  Start Trial
Sigma-Aldrich ⤷  Start Trial 410225_SIAL ⤷  Start Trial
Sigma-Aldrich ⤷  Start Trial G7126_SIGMA ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Glycine

Last updated: February 19, 2026

Glycine is a non-essential amino acid used in pharmaceutical, nutraceutical, and food industries. Its bulk sourcing involves chemical synthesis, fermentation, or extraction from natural sources. Major API producers and suppliers operate globally, offering varying qualities and certifications.

What Are the Major API Sourcing Methods for Glycine?

Chemical Synthesis

  • Produces synthetic glycine via routes such as:
    • Chloramine-T oxidation of amino acetic acid.
    • Strecker synthesis involving aldehydes and ammonia.
  • Advantages: Consistent chemical purity, scalable.
  • Drawbacks: Potential environmental concerns, higher cost.

Fermentation

  • Uses microbial fermentation of glucose or other substrates.
  • Produces biologically equivalent glycine.
  • Advantages: Lower environmental impact, high purity.
  • Drawbacks: Longer production cycles, complex control processes.

Extraction

  • Derived from natural protein hydrolysis (e.g., collagen or gelatin).
  • Less common for bulk APIs due to variability and complexity.

Global API Suppliers for Glycine

Supplier Location Certification Production Method Annual Production Capacity (Approx.) Notes
Ajinomoto Co. Japan GMP, ISO 9001 Fermentation 10,000+ tons Leading global producer, high purity
Evonik Industries Germany GMP, ISO Chemical synthesis 5,000+ tons Focus on pharmaceutical grade
Shaanxi Fuhuiyuan Bio-Tech China GMP, ISO Fermentation 3,000+ tons Cost competitive, growing export
Tokyo Chemical Industry Japan GMP, ISO Chemical synthesis Not specified Provides industry-grade APIs
CJ CheilJedang South Korea GMP, ISO Fermentation Data unavailable Focus on high-quality amino acids

Notable API Quality Standards and Certifications

  • GMP (Good Manufacturing Practice): Required for pharmaceutical APIs.
  • ISO 9001: Quality management certification.
  • FDA Registration: Necessary for US market.
  • EU Good Manufacturing Practice: Certification for European markets.

Regional Market Dynamics

  • Asia-Pacific: Largest production hub, led by China and India. Cost advantages dominate.
  • Europe: Focuses on high-quality, sterile, pharmaceutical-grade glycine.
  • North America: Relying on imports; compliance with FDA standards critical.

Quality Considerations

  • Purity levels typically above 99.5% for pharmaceutical use.
  • Residual ammonia, chlorinated compounds, or by-products must be within limits.
  • Certificates of Analysis (COA) mandated for batch release.

Supply Chain Considerations

  • Lead times vary from weeks (for existing stocks) to months (for custom orders).
  • Suppliers maintaining cold chain or secure storage for sensitive APIs.
  • Long-term contracts preferred for stable supply.

Regulatory and Trade Implications

  • Import/export tariffs influence region-to-region costs.
  • API suppliers often register with regulatory authorities like the FDA or EMA.
  • Pharmacopoeia standards (USP, Ph. Eur., JP) dictate acceptable specifications.

Supply Risks and Market Trends

  • API supply chains vulnerable to geopolitical shifts, trade restrictions.
  • Increased investment in fermentation technology for sustainability.
  • Growing demand for pharmaceutical-grade glycine, especially in Asia-Pacific.

Key Takeaways

  • Major suppliers include Ajinomoto, Evonik, Shaanxi Fuhuiyuan, Tokyo Chemical Industry, and CJ CheilJedang.
  • The primary production methods are fermentation and chemical synthesis, each with distinct cost and purity profiles.
  • Certification standards such as GMP and ISO are crucial for pharmaceutical APIs.
  • Geographic hubs influence quality, cost, and supply chain stability.
  • Regulatory compliance remains essential for market access, with increasingly stringent standards shaping supply dynamics.

FAQs

1. What is the main difference between synthetic and fermentation-produced glycine?
Synthetic glycine is produced chemically, offering high purity and scalability. Fermentation uses microbial processes, which are potentially more sustainable but may involve longer production times.

2. Which regions dominate glycine API manufacturing?
Asia-Pacific leads, especially China and India. Europe and North America focus on quality-certified, pharmaceutical-grade glycine.

3. What certifications are required for pharmaceutical API suppliers?
GMP certification is mandatory; ISO 9001 is common for quality management. Suppliers targeting US markets often seek FDA registration.

4. How does supply chain stability affect glycine availability?
Supply chains vulnerable to geopolitical risks, raw material availability, or regulatory changes can impact lead times and prices.

5. Are natural extraction methods viable for bulk API supply?
Extraction from natural sources is less common due to variability in raw material composition, cost, and complexity compared to fermentation and chemical synthesis.


References

[1] European Pharmacopoeia. (2021). Glycine monograph.
[2] Ajinomoto Co. Inc. (2022). Product catalog.
[3] Evonik Industries. (2022). Amino acids manufacturing overview.
[4] U.S. Food and Drug Administration. (2022). API registration requirements.
[5] China Food and Drug Administration. (2022). API production standards.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.